Status:

COMPLETED

THUNDER: Acute Ischemic Stroke Study with the Penumbra System® Including Thunderbolt™ Aspiration Tubing

Lead Sponsor:

Penumbra Inc.

Conditions:

Acute Ischemic Stroke

Large Vessel Occlusion

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke...

Eligibility Criteria

Inclusion

  • Patient age 18 - 80 years
  • Treatment within 8 hours of symptom onset
  • Pre-stroke mRS 0-2
  • Patient experiencing acute ischemic stroke secondary to intracranial large vessel occlusion in the internal carotid, middle cerebral (M1 or M2), basilar, or vertebral artery
  • If patient is eligible for thrombolytic therapy, it was administered as soon as possible, and no later than 3 hours from stroke symptom onset
  • Planned frontline treatment with Penumbra System including Thunderbolt modulated aspiration
  • Informed consent obtained per Institution Review Board/Ethics Committee requirements

Exclusion

  • Stenosis, excessive tortuosity, or any occlusion in a proximal vessel requiring treatment or preventing access to the thrombus
  • Alberta Stroke Program Early CT Score (ASPECTS) ≤6 or core infarct volume \>50 mL on MRI or CT-based imaging (for anterior circulation strokes)
  • Pregnant patient
  • Life expectancy \< 90 days due to comorbidities
  • Current participation in an interventional drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
  • Other medical, behavioral, or psychological conditions that in the opinion of the Investigator could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study

Key Trial Info

Start Date :

August 11 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 10 2024

Estimated Enrollment :

216 Patients enrolled

Trial Details

Trial ID

NCT05437055

Start Date

August 11 2022

End Date

December 10 2024

Last Update

January 29 2025

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Abrazo West Campus

Goodyear, Arizona, United States, 85395

2

Sharp Grossmont

San Diego, California, United States, 92123

3

HRI - Swedish

Englewood, Colorado, United States, 80113

4

Yale New Haven

New Haven, Connecticut, United States, 06520